{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:35Z","timestamp":1792515755717,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"25","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,7,7]]},"DOI":"10.1038\/s41388-026-03711-1","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:25:52Z","timestamp":1779463552000},"page":"2491-2505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["GPX8+ cancer-associated fibroblast-derived lactate contributes to lenvatinib resistance by facilitating BRPF1 expression through histone H3 lysine 18 lactylation in hepatocellular carcinoma"],"prefix":"10.1038","volume":"45","author":[{"given":"Qinsi","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhou","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9443-7075","authenticated-orcid":false,"given":"Jinglin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0086-8165","authenticated-orcid":false,"given":"Mingyan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"3711_CR1","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"3711_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jhep.2005.10.002","volume":"44","author":"HB El-Serag","year":"2006","unstructured":"El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, et al. Treatment and outcomes of treating of hepatocellular carcinoma among medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158\u201366.","journal-title":"J Hepatol"},{"key":"3711_CR3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450\u201362.","journal-title":"N Engl J Med"},{"key":"3711_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2016;2:16018.","journal-title":"Nat Rev Dis Prim"},{"key":"3711_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jhep.2022.09.006","volume":"78","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, et al. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. J Hepatol. 2023;78:133\u201341.","journal-title":"J Hepatol"},{"key":"3711_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","volume":"17","author":"Y Chen","year":"2024","unstructured":"Chen Y, Dai S, Cheng CS, Chen L. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J Hematol Oncol. 2024;17:130.","journal-title":"J Hematol Oncol"},{"key":"3711_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-91442-8_13","volume":"211","author":"S Zsch\u00e4bitz","year":"2018","unstructured":"Zsch\u00e4bitz S, Gr\u00fcllich C. et al. Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFR\u03b1, KIT and RET. Recent Results Cancer Res. 2018;211:187\u201398.","journal-title":"Recent Results Cancer Res"},{"key":"3711_CR8","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.3390\/cells10092418","volume":"10","author":"P Phan","year":"2021","unstructured":"Phan P, Saikia BB, Sonnaila S, Agrawal S, Kumar TKS. et al. The saga of endocrine FGFs. Cells. 2021;10:2418.","journal-title":"Cells"},{"key":"3711_CR9","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.1517","volume":"7","author":"M Matsuki","year":"2018","unstructured":"Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7:2641\u201353.","journal-title":"Cancer Med"},{"key":"3711_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1047-6","volume":"18","author":"C Lu","year":"2019","unstructured":"Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019;18:130.","journal-title":"Mol Cancer"},{"key":"3711_CR11","doi-asserted-by":"publisher","first-page":"3778.","DOI":"10.3390\/ijms23073778","volume":"23","author":"Z Sas","year":"2022","unstructured":"Sas Z, Cendrowicz E, Weinh\u00e4user I, Rygiel TP. Tumor microenvironment of hepatocellular carcinoma: challenges and opportunities for new treatment options. Int J Mol Sci. 2022;23:3778.","journal-title":"Int J Mol Sci"},{"key":"3711_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32283-3","volume":"13","author":"Y Lu","year":"2022","unstructured":"Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li Y, et al. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat Commun. 2022;13:4594.","journal-title":"Nat Commun"},{"key":"3711_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","volume":"3","author":"D Lavie","year":"2022","unstructured":"Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3:793\u2013807.","journal-title":"Nat Cancer"},{"key":"3711_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/hep.31792","volume":"73","author":"M Song","year":"2021","unstructured":"Song M, He J, Pan QZ, Yang J, Zhao J, Zhang YJ, et al. Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression. Hepatology. 2021;73:1717\u201335.","journal-title":"Hepatology"},{"key":"3711_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174\u201386.","journal-title":"Nat Rev Cancer"},{"key":"3711_CR16","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1101\/gad.279737.116","volume":"30","author":"P Gascard","year":"2016","unstructured":"Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30:1002\u201319.","journal-title":"Genes Dev"},{"key":"3711_CR17","doi-asserted-by":"publisher","first-page":"158.","DOI":"10.3390\/cells7100158","volume":"7","author":"P Procacci","year":"2018","unstructured":"Procacci P, Moscheni C, Sartori P, Sommariva M, Gagliano N. Tumor\u207bstroma cross-talk in human pancreatic ductal adenocarcinoma: a focus on the effect of the extracellular matrix on tumor cell phenotype and invasive potential. Cells. 2018;7:158.","journal-title":"Cells"},{"key":"3711_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12:153\u201386.","journal-title":"Annu Rev Pathol"},{"key":"3711_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02106-8","volume":"23","author":"Z Lin","year":"2024","unstructured":"Lin Z, Li G, Jiang K, Li Z, Liu T. Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications. Mol Cancer. 2024;23:191.","journal-title":"Mol Cancer"},{"key":"3711_CR20","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1089\/ars.2008.2055","volume":"10","author":"SC Tosatto","year":"2008","unstructured":"Tosatto SC, Bosello V, Fogolari F, Mauri P, Roveri A, Toppo S, et al. The catalytic site of glutathione peroxidases. Antioxid Redox Signal. 2008;10:1515\u201326.","journal-title":"Antioxid Redox Signal"},{"key":"3711_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.812811","volume":"12","author":"Z Ren","year":"2022","unstructured":"Ren Z, He Y, Yang Q, Guo J, Huang H, Li B, et al. A comprehensive analysis of the glutathione peroxidase 8 (GPX8) in human cancer. Front Oncol. 2022;12:812811.","journal-title":"Front Oncol"},{"key":"3711_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8025055","volume":"2022","author":"ZS Yang","year":"2022","unstructured":"Yang ZS, Yang Q, Sun XX, Xiong K, Zhu XT, Wang YC, et al. GPX8 as a novel prognostic factor and potential therapeutic target in primary glioma. J Immunol Res. 2022;2022:8025055.","journal-title":"J Immunol Res"},{"key":"3711_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.878546","volume":"12","author":"X Zhang","year":"2022","unstructured":"Zhang X, Xu H, Zhang Y, Sun C, Li Z, Hu C, et al. Immunohistochemistry and bioinformatics identify GPX8 as a potential prognostic biomarker and target in human gastric cancer. Front Oncol. 2022;12:878546.","journal-title":"Front Oncol"},{"key":"3711_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01692-z","volume":"20","author":"H Chen","year":"2020","unstructured":"Chen H, Xu L, Shan ZL, Chen S, Hu H. GPX8 is transcriptionally regulated by FOXC1 and promotes the growth of gastric cancer cells through activating the Wnt signaling pathway. Cancer Cell Int. 2020;20:596.","journal-title":"Cancer Cell Int"},{"key":"3711_CR25","doi-asserted-by":"publisher","first-page":"21420","DOI":"10.1073\/pnas.2010275117","volume":"117","author":"A Khatib","year":"2020","unstructured":"Khatib A, Solaimuthu B, Ben Yosef M, Abu Rmaileh A, Tanna M, Oren G, et al. The glutathione peroxidase 8 (GPX8)\/IL-6\/STAT3 axis is essential in maintaining an aggressive breast cancer phenotype. Proc Natl Acad Sci USA. 2020;117:21420\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3711_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.152","volume":"3","author":"YL Xu","year":"2022","unstructured":"Xu YL, Yuan LW, Jiang XM, Su MX, Huang MY, Chen YC, et al. Glutathione peroxidase 8 expression on cancer cells and cancer-associated fibroblasts facilitates lung cancer metastasis. MedComm. 2022;3:e152.","journal-title":"MedComm"},{"key":"3711_CR27","doi-asserted-by":"publisher","first-page":"8758","DOI":"10.1073\/pnas.1433065100","volume":"100","author":"A Dey","year":"2003","unstructured":"Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci USA. 2003;100:8758\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3711_CR28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s42003-021-02405-6","volume":"4","author":"CL Cheng","year":"2021","unstructured":"Cheng CL, Tsang FH, Wei L, Chen M, Chin DW, Shen J, et al. Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. Commun Biol. 2021;4:888.","journal-title":"Commun Biol"},{"key":"3711_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.655152","volume":"9","author":"X Geng","year":"2021","unstructured":"Geng X, Chen H, Zhao L, Hu J, Yang W, Li G, et al. Cancer-associated fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer. Front Cell Dev Biol. 2021;9:655152.","journal-title":"Front Cell Dev Biol"},{"key":"3711_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41:421\u201333.","journal-title":"Cancer Cell"},{"key":"3711_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.freeradbiomed.2014.01.018","volume":"70","author":"T Ramming","year":"2014","unstructured":"Ramming T, Hansen HG, Nagata K, Ellgaard L, Appenzeller-Herzog C. GPx8 peroxidase prevents leakage of H2O2 from the endoplasmic reticulum. Free Radic Biol Med. 2014;70:106\u201316.","journal-title":"Free Radic Biol Med"},{"key":"3711_CR32","doi-asserted-by":"publisher","first-page":"1503.","DOI":"10.3390\/antiox10101503","volume":"10","author":"HA Lee","year":"2021","unstructured":"Lee HA, Chu KB, Moon EK, Quan FS. Glutathione peroxidase 8 suppression by histone deacetylase inhibitors enhances endoplasmic reticulum stress and cell death by oxidative stress in hepatocellular carcinoma cells. Antioxidants. 2021;10:1503.","journal-title":"Antioxidants"},{"key":"3711_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3233\/CBM-160424","volume":"19","author":"N Yang","year":"2017","unstructured":"Yang N, Qu YJ, Cheng Y, Liang T, Zhang MN, Zhang D, et al. Endoplasmic reticulum stress regulates proliferation, migration and invasion of human ovarian cancer SKOV3 cells through PI3K\/AKT\/mTOR signaling pathway. Cancer Biomark. 2017;19:263\u20139.","journal-title":"Cancer Biomark"},{"key":"3711_CR34","first-page":"7886","volume":"17","author":"LJ Li","year":"2018","unstructured":"Li LJ, Chai Y, Guo XJ, Chu SL, Zhang LS. Effects of endoplasmic reticulum stress on autophagy and apoptosis of human leukemia cells via inhibition of the PI3K\/AKT\/mTOR signaling pathway. Mol Med Rep. 2018;17:7886\u201392.","journal-title":"Mol Med Rep"},{"key":"3711_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1610466","volume":"16","author":"Z Xu","year":"2025","unstructured":"Xu Z, Wang X, Cheng H, Li J, Zhang X, Wang X. The role of MCT1 in tumor progression and targeted therapy: a comprehensive review. Front Immunol. 2025;16:1610466.","journal-title":"Front Immunol"},{"key":"3711_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen J, Huang Z, Chen Y, Tian H, Chai P, Shen Y, et al. Lactate and lactylation in cancer. Signal Transduct Target Ther. 2025;10:38.","journal-title":"Signal Transduct Target Ther"},{"key":"3711_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1053\/j.gastro.2023.01.023","volume":"164","author":"M Lim","year":"2023","unstructured":"Lim M, Franses JW, Imperial R, Majeed U, Tsai J, Hsiehchen D. EGFR\/ERBB2 amplifications and alterations associated with resistance to lenvatinib in hepatocellular carcinoma. Gastroenterology. 2023;164:1006\u20138.e3.","journal-title":"Gastroenterology"},{"key":"3711_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-024-01600-2","volume":"17","author":"F Zhang","year":"2024","unstructured":"Zhang F, Ma Y, Li D, Wei J, Chen K, Zhang E, et al. Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution. J Hematol Oncol. 2024;17:80.","journal-title":"J Hematol Oncol"},{"key":"3711_CR39","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/1078-0432.CCR-15-2851","volume":"23","author":"HM Brechbuhl","year":"2017","unstructured":"Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, et al. Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin Cancer Res. 2017;23:1710\u201321.","journal-title":"Clin Cancer Res"},{"key":"3711_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14134-w","volume":"11","author":"F Pelon","year":"2020","unstructured":"Pelon F, Bourachot B, Kieffer Y, Magagna I, Mermet-Meillon F, Bonnet I, et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat Commun. 2020;11:404.","journal-title":"Nat Commun"},{"key":"3711_CR41","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/ncb3478","volume":"19","author":"A Labernadie","year":"2017","unstructured":"Labernadie A, Kato T, Brugu\u00e9s A, Serra-Picamal X, Derzsi S, Arwert E, et al. A mechanically active heterotypic E-cadherin\/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat Cell Biol. 2017;19:224\u201337.","journal-title":"Nat Cell Biol"},{"key":"3711_CR42","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-24-1816","volume":"85","author":"J Zhan","year":"2025","unstructured":"Zhan J, Li M, Li L, Zeng TT, Liu J, Chen Q, et al. Targeting LTBP2 derived from cancer-associated fibroblasts sensitizes esophageal squamous cell carcinoma to chemotherapy. Cancer Res. 2025;85:2412\u201328.","journal-title":"Cancer Res"},{"key":"3711_CR43","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1111\/1759-7714.13671","volume":"11","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu Y, Guo Y, Zhao Q. GPX8 promotes migration and invasion by regulating epithelial characteristics in non-small cell lung cancer. Thorac Cancer. 2020;11:3299\u2013308.","journal-title":"Thorac Cancer"},{"key":"3711_CR44","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.4252\/wjsc.v12.i11.1410","volume":"12","author":"P Jagust","year":"2020","unstructured":"Jagust P, Alcal\u00e1 S, Sainz B Jr, Heeschen C, Sancho P. Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells. World J Stem Cells. 2020;12:1410\u201328.","journal-title":"World J Stem Cells"},{"key":"3711_CR45","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s13402-024-00934-w","volume":"47","author":"CY Tao","year":"2024","unstructured":"Tao CY, Wu XL, Song SS, Tang Z, Zhou YF, Tian MX, et al. Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration. Cell Oncol. 2024;47:1391\u2013403.","journal-title":"Cell Oncol"},{"key":"3711_CR46","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","volume":"29","author":"S Halford","year":"2023","unstructured":"Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, et al. A phase I Dose-escalation Study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin Cancer Res. 2023;29:1429\u201339.","journal-title":"Clin Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03711-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03711-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03711-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:07:29Z","timestamp":1781561249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03711-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":46,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026,7,7]]}},"alternative-id":["3711"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03711-1","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods used to generate the data in this paper were performed in accordance with relevant guidelines and regulations. All experiments using human samples were performed as approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University [Approval number: (2024)CDYFYYLK(08-097)]. All participants provided informed consent for their tissue samples to be used in research. All mouse experiments were performed as approved by the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Nanchang University [Approval number: CDYFY-IACUC-202501GR136].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}